Tick-Borne Encephalitis (TBE) Vaccination in Children: Advantage of the Rapid Immunization Schedule (i.e., days 0, 7, 21)

Schoendorf, Ines; Ternák, Gábor; Oroszlán, György; Nicolay, Uwe; Banzhoff, Angelika; Zent, Olaf

doi:10.4161/hv.3.2.3747

Cited by 29 publications

(16 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, after three complete doses of INV, N titers peaked at 2 mo and then progressively declined, and animals were not completely protected as evidenced by detectable (albeit low-level) postchallenge viremia. The three-dose INV immunization schedule in our NHP experiments resembled a rapid immunization schedule used for one of the available INVs, Encepur (days 0, 7, and 21), which was shown to be as effective in humans as the conventional schedule (30,31). A significant decline in seroconversion 6 mo after administration of the INV was observed independently of the schedule used (31).…”

Section: Discussionmentioning

confidence: 93%

Single-dose vaccine against tick-borne encephalitis

Rumyantsev¹,

Goncalvez²,

Giel–Moloney³

et al. 2013

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Tick-borne encephalitis (TBE) virus is the most important human pathogen transmitted by ticks in Eurasia. Inactivated vaccines are available but require multiple doses and frequent boosters to induce and maintain immunity. Thus far, the goal of developing a safe, live attenuated vaccine effective after a single dose has remained elusive. Here we used a replication-defective (single-cycle) flavivirus platform, RepliVax, to generate a safe, single-dose TBE vaccine. Several RepliVax-TBE candidates attenuated by a deletion in the capsid gene were constructed using different flavivirus backbones containing the envelope genes of TBE virus. RepliVax-TBE based on a West Nile virus backbone (RV-WN/TBE) grew more efficiently in helper cells than candidates based on Langat E5, TBE, and yellow fever 17D backbones, and was found to be highly immunogenic and efficacious in mice. Live chimeric yellow fever 17D/TBE, Dengue 2/TBE, and Langat E5/TBE candidates were also constructed but were found to be underattenuated. RV-WN/TBE was demonstrated to be highly immunogenic in Rhesus macaques after a single dose, inducing a significantly more durable humoral immune response compared with three doses of a licensed, adjuvanted human inactivated vaccine. Its immunogenicity was not significantly affected by preexisting immunity against WN. Immunized monkeys were protected from a stringent surrogate challenge. These results support the identification of a single-cycle TBE vaccine with a superior product profile to existing inactivated vaccines, which could lead to improved vaccine coverage and control of the disease.flavivirus vaccine | prophylaxis | preclinical | nonhuman primate

show abstract

Section: Discussionmentioning

confidence: 93%

Single-dose vaccine against tick-borne encephalitis

Rumyantsev¹,

Goncalvez²,

Giel–Moloney³

et al. 2013

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…The interval after the initial dose may be reduced to 1-2 weeks for rapid protection. Investigations comparing rapid immunization (vaccination on days 0, 7 and 21) versus conventional schedules of Ence-purÒ revealed a similar protection efficacy [86,87]. The Russian vaccines are licensed for adults and children older than 3 years (Table 1) but are not authorized by the EMA for use in the EU [69,88].…”

Section: Immunization Strategies and Schedulesmentioning

confidence: 99%

EAN consensus review on prevention, diagnosis and management of tick‐borne encephalitis

Taba

Schmutzhard

Forsberg

et al. 2017

Euro J of Neurology

169

185

View full text Add to dashboard Cite

show abstract

“…Both vaccines offer the option of basic immunization on days 0 and 14 followed by the third dose at 5(9)-12 months. Alternatively, Encepur can also be administered on days 0, 7, and 21 in a fast-track regimen, followed by a fourth dose at 12-18 months [4].…”

Section: Vaccination Intervalsmentioning

confidence: 99%

TBE—update on vaccination recommendations for children, adolescents, and adults

Jelı́nek¹

2012

Wien Med Wochenschr

View full text Add to dashboard Cite

Vaccines against tick-born encephalitis (TBE) are well established in Europe. Two highly immunogenic and safe products are available, FSME-IMMUN and Encepur. Extensive research has been published regarding all aspects of standard and rapid immunization schedules, covaccination, and vaccine interchangeability. Long-term effectiveness and resulting recommendations for booster intervals remain topics of discussion. Vaccination is recommended in Switzerland and in Germany for adults and children living in, or travelling to, endemic areas. Austria has recommended universal vaccination since 1981. It is noteworthy that Austria is the only country in Europe that has experienced a decrease in caseload during the last 20 years. This is almost certainly due to the very high vaccine coverage rate of 86 %.

show abstract

Tick-Borne Encephalitis (TBE) Vaccination in Children: Advantage of the Rapid Immunization Schedule (i.e., days 0, 7, 21)

Cited by 29 publications

References 20 publications

Single-dose vaccine against tick-borne encephalitis

Single-dose vaccine against tick-borne encephalitis

EAN consensus review on prevention, diagnosis and management of tick‐borne encephalitis

TBE—update on vaccination recommendations for children, adolescents, and adults

Contact Info

Product

Resources

About